Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimozide in Patients With Amyotrophic Lateral Sclerosis
NCT03272503Phase 2Unknown
- Sponsor
- University of Calgary
- Start
- Oct 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pimozide in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by University of Calgary. Primary endpoint: ALS Functional Rating Scale-Revised at 26 weeks. Status: unknown.
02
Drugs
pimozide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03272503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272503.